Replies to post #465172 on NorthWest Biotherapeutics Inc (NWBO)

[NRF]

Much obliged, share the link someway somehow if you do?

[sentiment_stocks]

I think you may run into rebroadcasting rights in doing so; therefore, I would instead suggest that interested shareholders plop down the $120 it costs to watch the virtual presentation of LL's event.

It would be nice to see a large group of NWBO shareholders support the NYAS and sign-up for the live presentation of Dr. Liau to hear what she has to say.

I believe that the following passage was sent out in an email blast by the Frontiers in Cancer Immunotherapy. Having already signed up for the event, I'd have thought I would have received this email, but I didn't. I think, therefore, that it may have been in an email blast to either the press, or to actual NYAS members.

The below statement is from the Frontiers in Cancer Immunotherapy email blast:

In addition to newly added speakers Dr. Ivana Djuretic, PhD, from Asher Biotherapeutics and Dr. Linda Liau from UCLA, we posted the competitively selected short talk presentations and the panelists who will be discussing “How to turn cold tumor into a hot tumor”.

Don’t miss Dr. Liau’s presentation! In her lecture “Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma,” she will be sharing exciting updates from her Phase 3 Glioblastoma Multiforme clinical trial.

It's my understanding that the New York Academy of Sciences has been very accommodating to Northwest Bio, given all their multiple balls in the air (e.g. Journal rules, NYAS rules, etc.), and contending trip wires (Lawyer rules, SEC rules) right now.

I believe that while any journal the company is working closely together with to publish the long-awaited trial data is okay with some of the data being presented by a non-employee (which Dr. Liau is) at a scientific conference, apparently, they are NOT okay with that same data being PR'd. It is not the business of these journals, who are, in a sense, the medical press, to be altruistic in their nature, with "red hot" news. They all want to be the ones breaking the "red hot" news in order to sell their journals, and the articles contained within them. So if the company wants to publish their results in a journal (which apparently has shown to improve one's chances of regulatory approval), they have to follow the rules of that particular journal.

Therefore, while the company may choose to PR the upcoming event LL will be speaking about, [I]it is now my understanding that they will NOT release the actual "exciting" content (I mean the data) that she will be discussing at this event as it will likely violate the rules of the journal.

It is likely that some in the press WILL cover this NYAS event, and so it is very possible LL's event will receive some press coverage.

So again, I hope various shareholders will sign up for the event which, IMO, would show support for Dr. Liau, NYAS, and the company. Plus, it seems, this represents an opportunity to hear some of the "exciting" updates on the P3 trial.

https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/websitePage:6415ad40-8fcf-40db-8dc0-dde9ad5e065e